Sort
82,697 grants matching “vaccine development”
ANTI-VIRAL IMMUNE MECHANISMS IN EARLY CHILDHOOD
$855,794Stanford University · P01 · FY2003 · AI
Vaccine and Treatment Evaluation Unit at Saint Louis University
$855,721Daniel F. Hoft · Saint Louis University · UM1 · FY2023 · AI
Immune Modulation/Hematopoietic Cell Transplantation
$855,695Dana-Farber Cancer Institute · U19 · FY2005 · AI
Controlled Infection Trial to Test Efficacy of Hookworm Vaccine with Different TLR Agonists
$855,527David Joseph Diemert · George Washington University · U01 · FY2018 · AI
International Training in AIDS-Related Epidemiology
$855,400Myron E Essex · Harvard School Of Public Health · D43 · FY2007 · TW
A proprietary single-cell analytics platform for accelerating biologics manufacturing
$855,264Ayca Yalcin Ozkumur · Onecyte Biotechnologies, Inc. · R44 · FY2022 · TR
A proprietary single-cell analytics platform for accelerating biologics manufacturing
$855,264Ayca Yalcin Ozkumur · Onecyte Biotechnologies, Inc. · R44 · FY2021 · TR
Targeted genetic engineering of B cells to induce protective antibody responses to viral pathogens
$855,174Jennifer Eileen Adair · Fred Hutchinson Cancer Center · R01 · FY2024 · AI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
$855,154Ofer Levy · Boston Children'S Hospital · U19 · FY2021 · AI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses
$855,154Ofer Levy · Boston Children'S Hospital · U19 · FY2021 · AI
Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity
$855,143Ann C Duerr · Fred Hutchinson Cancer Research Center · R01 · FY2008 · DE
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
$855,091Joel D. Ernst · University Of California, San Francisco · R01 · FY2023 · AI
Project 3: Defining the antibody landscape after SARS-CoV-2 infection
$855,062Sabra L Klein · Johns Hopkins University · U54 · FY2020 · CA
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
$855,061Beatrice H Hahn · University Of Pennsylvania · R37 · FY2022 · AI
T Cell Immune Responses To HIV And Other Pathogens
$855,058Daniel Cesar Douek · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Immunogen design to elicit polyclonal bNAb responses to the V3 glycan supersite
$855,055Kevin Wiehe · University Of Pennsylvania · P01 · FY2025 · AI
Optimizing Humoral Responses to HIV-1 Env Vaccine Antigens
$855,054Garnett H Kelsoe · University Of Pennsylvania · P01 · FY2025 · AI
Role of B Lymphocytes In HIV Infection And Pathogenesis
$855,034Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
HIV-1 Env structure and function assessed by parallel smFRET and cryoET
$854,998Walther H Mothes · Yale University · R01 · FY2019 · AI
"Acquisition of a Multi-functional Cryo Scanning Electron Microscope (SEM)"
$854,915Mary Ann Y Jabra-Rizk · University Of Maryland Baltimore · S10 · FY2021 · OD
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect
$854,905Wolfgang W Scholz · Mabvax Therapeutics, Inc. · R44 · FY2012 · CA
A San Francisco Street Youth Cohort: At Risk and HIV+
$854,879Anna-Barbara None Moscicki · University Of California, San Francisco · U01 · FY2010 · HD
Development Of Vaccines For Genital Herpes Simplex Infection
$854,802Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Novel Therapeutics for Biodefense
$854,748Paratek Pharmaceuticals · R43 · FY2005 · AI
Vector-borne pathogen transmission
$854,602Shaden Kamhawi · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI